Skip to content

Rate Adaptive Atrial Pacing in Heart Failure

Rate Adaptive Atrial Pacing in Heart Failure Patients With Chronotropic Incompetence

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03235843
Acronym
ADAPTION
Enrollment
65
Registered
2017-08-01
Start date
2017-08-01
Completion date
2019-12-01
Last updated
2017-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronotropic Incompetence, Heart Failure, ICD

Keywords

Chronotropic Incompetence, Rate Adaptive Pacing, Minute Ventilation Sensor, Primary Prevention ICD Therapy, Implantable Cardioverter Defibrillator, Heart Failure, Exercise Intolerance

Brief summary

The ADAPTION trial is an investigator initiated prospective randomized doubleblind cross-over pilot study in a multi-center setting. Aim: to assess the ability of minute ventilation (MV) sensor driven rate adaptive atrial stimulation to restore functional capacity and quality of life in heart failure patients with chronotropic incompetence. Methods: heart failure patients (left ventricular ejection fraction ≤35% & New York Heart Assessment II or III) who were implanted with a 2-chamber implantable cardioverter defibrillator (ICD) device equipped with a MV sensor that are diagnosed with chronotropic incompetence will be included in the study. Patients will be randomized in a 1:1 fashion to rate responsive pacing (MV sensor only) function ON (AAIR mode) or OFF (DDI mode). After 3 months the pacing mode will be switched to the opposite mode.

Interventions

DEVICEAAIR pacing

Rate adaptive pacing using a MV sensor.

DEVICEDDI-pacing

Rate adaptive pacing OFF

Sponsors

UMC Utrecht
CollaboratorOTHER
Maasstad Hospital
CollaboratorOTHER
Northwest Clinics Alkmaar
CollaboratorUNKNOWN
Amsterdam UMC, location VUmc
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

The pacing mode set by the pacemaker technician will not be disclosed to either patients or the study physician.

Intervention model description

Patients enter a double blind randomized cross-over pilot study and will be randomized in a 1:1 fashion to either rate responsive (MV sensor only) function on or off. After 3 months the pacing mode will be switched to the opposite mode.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Chronotropic incompetence as assessed by a modified Heart Rate Score (mHRS) 2. Implanted with a Boston Scientific dual chamber ICD equipped with minute ventilation sensor 3. Symptomatic congestive heart failure (NYHA class II-III) 4. Left ventricular systolic dysfunction (LVEF \<35%) 5. Optimal medical therapy 6. Sinus rhythm 7. Subjects should be able to perform normal daily activities

Exclusion criteria

1. Age \<18 or incapacitated adult 2. Documented atrial fibrillation in the last 3 months prior to inclusion 3. Indication for pacing (SSS, AV conduction abnormalities requiring pacing) 4. Respiratory rate abnormalities (hyperventilation) or use of a mechanical ventilator 5. Patients who are unable to tolerate increased pacing rates 6. Indication for cardiac resynchronization therapy Beta-blocker / ivabradine / amiodarone therapy is not an exclusion criterion

Design outcomes

Primary

MeasureTime frameDescription
Improvement of quality of life3 months after changing the pacing modeMeasured with the Minnesota Living with Heart Failure Questionnaire

Secondary

MeasureTime frameDescription
Improvement of functional capacity3 months after changing the pacing modeMeasured with a six-minute walk test
Reversibility of chronotropic incompetence3 months after changing the pacing modeA comparison of the modified HeartRateScore with and without rate adaptive pacing.
Clinical status3 months after changing the pacing modeMeasured with NYHA class assessment and number of hospitalizations for heart failure.
Daily activity level3 months after changing the pacing modeMeasured with the device's accelerometer

Countries

Netherlands

Contacts

Primary ContactCornelis P Allaart, MD, PhD
cp.allaart@vumc.nl+31 (0)20 4445043
Backup ContactAnne-Lotte CJ van der Lingen, MD
a.vanderlingen@vumc.nl+31 (0)20 4443272

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026